Alterations to in Hematologic Malignancies

Overview

Journal Cancer Res

Specialty Oncology

Date 2020 Oct 22

PMID 33087320

Citations 11

Authors

Kartika Venugopal

Yang Feng

Daniil Shabashvili

Olga A Guryanova

Affiliations

Soon will be listed here.

Abstract

In the last decade, large-scale genomic studies in patients with hematologic malignancies identified recurrent somatic alterations in epigenetic modifier genes. Among these, the DNA methyltransferase has emerged as one of the most frequently mutated genes in adult myeloid as well as lymphoid malignancies and in clonal hematopoiesis. In this review, we discuss recent advances in our understanding of the biochemical and structural consequences of mutations on DNA methylation catalysis and binding interactions and summarize their effects on epigenetic patterns and gene expression changes implicated in the pathogenesis of hematologic malignancies. We then review the role played by mutant in clonal hematopoiesis, accompanied by its effect on immune cell function and inflammatory responses. Finally, we discuss how this knowledge informs therapeutic approaches for hematologic malignancies with mutant .

Citing Articles

STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells.

Huang J, Xie J, Wang Y, Sheng M, Sun Y, Chen P Leukemia. 2025; .

PMID: 39987368 DOI: 10.1038/s41375-025-02542-5.

Significance of targeting DNMT3A mutations in AML.

Huang G, Cai X, Li D Ann Hematol. 2024; .

PMID: 39078434 DOI: 10.1007/s00277-024-05885-8.

DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis.

Xu S, Yuan Z, Jiang C, Chen W, Li Q, Chen T Adv Sci (Weinh). 2024; 11(16):e2308531.

PMID: 38380551 PMC: 11040361. DOI: 10.1002/advs.202308531.

Epigenetic Mechanisms in Hematologic Aging and Premalignant Conditions.

Yan B, Yuan Q, Guryanova O Epigenomes. 2023; 7(4).

PMID: 38131904 PMC: 10743085. DOI: 10.3390/epigenomes7040032.

The Role of Epigenetic Modifier Mutations in Peripheral T-Cell Lymphomas.

Tigu A, Bancos A Curr Issues Mol Biol. 2023; 45(11):8974-8988.

PMID: 37998740 PMC: 10670124. DOI: 10.3390/cimb45110563.

References

Coombs C, Sallman D, Devlin S, Dixit S, Mohanty A, Knapp K . Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016; 101(11):e457-e460. PMC: 5394875. DOI: 10.3324/haematol.2016.148999. View

Russler-Germain D, Spencer D, Young M, Lamprecht T, Miller C, Fulton R . The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014; 25(4):442-54. PMC: 4018976. DOI: 10.1016/j.ccr.2014.02.010. View

Norvil A, AlAbdi L, Liu B, Tu Y, Forstoffer N, Michie A . The acute myeloid leukemia variant DNMT3A Arg882His is a DNMT3B-like enzyme. Nucleic Acids Res. 2020; 48(7):3761-3775. PMC: 7144950. DOI: 10.1093/nar/gkaa139. View

Heyn P, Logan C, Fluteau A, Challis R, Auchynnikava T, Martin C . Gain-of-function DNMT3A mutations cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions. Nat Genet. 2018; 51(1):96-105. PMC: 6520989. DOI: 10.1038/s41588-018-0274-x. View

Watson C, Papula A, Poon G, Wong W, Young A, Druley T . The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020; 367(6485):1449-1454. DOI: 10.1126/science.aay9333. View

Mayle A, Yang L, Rodriguez B, Zhou T, Chang E, Curry C . Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2014; 125(4):629-38. PMC: 4304108. DOI: 10.1182/blood-2014-08-594648. View

Lu R, Wang J, Ren Z, Yin J, Wang Y, Cai L . A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis. Cancer Res. 2019; 79(14):3583-3594. PMC: 6897384. DOI: 10.1158/0008-5472.CAN-18-3275. View

Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi Y . Array-based genomic resequencing of human leukemia. Oncogene. 2010; 29(25):3723-31. DOI: 10.1038/onc.2010.117. View

Chaudry S, Chevassut T . Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis. Biomed Res Int. 2017; 2017:5473197. PMC: 5329657. DOI: 10.1155/2017/5473197. View

10.

Kramer A, Kothari A, Wilson W, Celik H, Nikitas J, Mallaney C . Dnmt3a regulates T-cell development and suppresses T-ALL transformation. Leukemia. 2017; 31(11):2479-2490. PMC: 5636646. DOI: 10.1038/leu.2017.89. View

11.

Thol F, Klesse S, Kohler L, Gabdoulline R, Kloos A, Liebich A . Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia. 2016; 31(6):1286-1295. PMC: 7610466. DOI: 10.1038/leu.2016.345. View

12.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

13.

Li X, Zhang Q, Ding Y, Liu Y, Zhao D, Zhao K . Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity. Nat Immunol. 2016; 17(7):806-15. DOI: 10.1038/ni.3464. View

14.

Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D . Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 2013; 121(23):4749-52. DOI: 10.1182/blood-2012-11-465138. View

15.

Coombs C, Zehir A, Devlin S, Kishtagari A, Syed A, Jonsson P . Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. 2017; 21(3):374-382.e4. PMC: 5591073. DOI: 10.1016/j.stem.2017.07.010. View

16.

Scourzic L, Couronne L, Pedersen M, Della Valle V, Diop M, Mylonas E . DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016; 30(6):1388-98. PMC: 4869893. DOI: 10.1038/leu.2016.29. View

17.

Patel J, Schumacher J, Frizzell K, Sorrells S, Shen W, Clayton A . Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia. Leuk Res. 2017; 56:7-12. DOI: 10.1016/j.leukres.2017.01.027. View

18.

Ferreira H, Heyn H, Vizoso M, Moutinho C, Vidal E, Gomez A . DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia. Oncogene. 2015; 35(23):3079-82. PMC: 4705435. DOI: 10.1038/onc.2015.359. View

19.

Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerova K, Haferlach T . Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. Leukemia. 2017; 32(2):295-302. DOI: 10.1038/leu.2017.239. View

20.

Grossmann V, Haferlach C, Weissmann S, Roller A, Schindela S, Poetzinger F . The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer. 2013; 52(4):410-22. DOI: 10.1002/gcc.22039. View